Thursday, August 18, 2022 12:16:01 PM
That depends :o)
All of this is from the Agreement itself:
This Agreement shall commence as of the Effective Date and, unless sooner terminated in accordance with the terms hereof or by mutual written consent, shall continue on a Product-by-Product and country-by-country basis, until the expiration of the Royalty Term (the “Term”).
“Royalty Term” means the period commencing upon the First Commercial Sale and ending upon the last to occur of: (a) the expiration of the last to expire IPI Patent that contains a Valid Claim Covering the Compound or the Product in the ALFASIGMA Territory; (b) the expiration of Regulatory Exclusivity for the sale of Product in the ALFASIGMA Territory; and (c) the tenth (10th) anniversary of the First Commercial Sale.
ALFASIGMA may terminate all development activities and this Agreement without cause at any time by giving 60 days’ prior written notice to IPI;
The agreement may terminate in the event of a Material Breach by either party.
This Agreement shall commence as of the Effective Date and, unless sooner terminated in accordance with the terms hereof or by mutual written consent, shall continue on a Product-by-Product and country-by-country basis, until the expiration of the Royalty Term (the “Term”).
“Royalty Term” means the period commencing upon the First Commercial Sale and ending upon the last to occur of: (a) the expiration of the last to expire IPI Patent that contains a Valid Claim Covering the Compound or the Product in the ALFASIGMA Territory; (b) the expiration of Regulatory Exclusivity for the sale of Product in the ALFASIGMA Territory; and (c) the tenth (10th) anniversary of the First Commercial Sale.
It's morally wrong to allow a sucker to keep his money.
......W. C. Fields
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM